259 related articles for article (PubMed ID: 26797085)
21. KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
Matson DR; Xu J; Huffman L; Barroilhet L; Accola M; Rehrauer WM; Weisman P
Am J Case Rep; 2017 May; 18():558-562. PubMed ID: 28526814
[TBL] [Abstract][Full Text] [Related]
22. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
23. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
[TBL] [Abstract][Full Text] [Related]
24. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
[TBL] [Abstract][Full Text] [Related]
25. Ovarian mucinous cystadenoma coexisting with benign Brenner tumor: MR imaging findings.
Kato H; Kanematsu M; Furui T; Morishige K; Hirose Y
Abdom Imaging; 2013 Apr; 38(2):412-6. PubMed ID: 22476372
[TBL] [Abstract][Full Text] [Related]
26. Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in "High-Risk" Lesions.
Conner JR; Mariño-Enríquez A; Mino-Kenudson M; Garcia E; Pitman MB; Sholl LM; Srivastava A; Doyle LA
Pancreas; 2017; 46(5):665-671. PubMed ID: 28196015
[TBL] [Abstract][Full Text] [Related]
27. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
[TBL] [Abstract][Full Text] [Related]
28. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
29. A histogenetic consideration of ovarian mucinous tumors based on an analysis of lesions associated with teratomas or Brenner tumors.
Nomura K; Aizawa S
Pathol Int; 1997 Dec; 47(12):862-5. PubMed ID: 9503468
[TBL] [Abstract][Full Text] [Related]
30. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
[TBL] [Abstract][Full Text] [Related]
31. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors.
Elias KM; Tsantoulis P; Tille JC; Vitonis A; Doyle LA; Hornick JL; Kaya G; Barnes L; Cramer DW; Puppa G; Stuckelberger S; Hooda J; Dietrich PY; Goggins M; Kerr CL; Birrer M; Hirsch MS; Drapkin R; Labidi-Galy SI
J Pathol; 2018 Dec; 246(4):459-469. PubMed ID: 30229909
[TBL] [Abstract][Full Text] [Related]
32. On the site of origin of epithelial tumors of the ovary.
Karseladze AI
Eur J Gynaecol Oncol; 2001; 22(2):110-5. PubMed ID: 11446472
[TBL] [Abstract][Full Text] [Related]
33. Benign epithelial ovarian tumors.
Tuncer ZS; Günalp S; Aksu T; Ayhan A
Eur J Gynaecol Oncol; 1998; 19(4):391-3. PubMed ID: 9744734
[TBL] [Abstract][Full Text] [Related]
34. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors.
Kondi-Pafiti A; Kairi-Vassilatou E; Iavazzo Ch; Vouza E; Mavrigiannaki P; Kleanthis Ch; Vlahodimitropoulos D; Liapis A
Arch Gynecol Obstet; 2012 Jun; 285(6):1699-702. PubMed ID: 22198845
[TBL] [Abstract][Full Text] [Related]
36. Flow cytometric DNA analysis of ovarian Brenner tumors and transitional cell carcinomas.
Martin AR; Kotylo PK; Kennedy JC; Fineberg NS; Roth LM
Int J Gynecol Pathol; 1992 Jul; 11(3):188-96. PubMed ID: 1399228
[TBL] [Abstract][Full Text] [Related]
37. Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
Shibata H; Ohike N; Norose T; Isobe T; Suzuki R; Imai H; Shiokawa A; Aoki T; Murakami M; Mizukami H; Tanaka JI; Takimoto M
Anticancer Res; 2017 Dec; 37(12):7063-7068. PubMed ID: 29187496
[TBL] [Abstract][Full Text] [Related]
38. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
Desouki MM; Khabele D; Crispens MA; Fadare O
Int J Gynecol Pathol; 2015 Jan; 34(1):19-24. PubMed ID: 25473748
[TBL] [Abstract][Full Text] [Related]
39. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
40. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors.
Seidman JD; Khedmati F
Arch Pathol Lab Med; 2008 Nov; 132(11):1753-60. PubMed ID: 18976011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
